US
Canada
3 Reasons Why Test-to-Treat is the Way of the Future
April 21, 2022
The next generation of test-to-treat diagnostics is here, and we’re on a mission to make healthcare accessible to all.
The next generation of test-to-treat diagnostics is here, and we’re on a mission to make healthcare accessible to all.
Lucira was the proud provider for COVID-19 testing for the RTCA for their annual dinner in Washington, D.C this past March.
As of January 15, private insurance companies are required to reimburse members for at-home COVID-19 test purchases. Read and learn how to obtain your reimbursement.
Learn what we know so far about Omicron’s subvariant BA.2. Read the blog now to stay informed.
This home test kit has not been FDA cleared or approved. This home test kit has been authorized by FDA under EUA. This home test kit has been authorized only for the testing of nasal swabs for detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This home test kit is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or revoked sooner.
These home tests have not been FDA cleared or approved. These home tests have been authorized by FDA under Emergency Use Authorization (EUA). These home tests have been authorized only for the testing of nasal swabs for detection of nucleic acid from SARS-CoV-2 alone, or from SARS-CoV-2, influenza A, and influenza B; not for any other viruses or pathogens. These home tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or revoked sooner.
Monday -Friday 7:00am-5:00pm PT
© 2023 Lucira Health, Inc. All rights reserved.
